Research programme: RHO kinase inhibitors - Boehringer Ingelheim
Latest Information Update: 16 Jul 2016
At a glance
- Originator Boehringer Ingelheim
- Class Isoquinolines; Quinazolinones
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (PO)
- 16 Aug 2009 Preclinical trials in Cardiovascular disorders in USA (PO)